Juliana Mansur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Juliana Mansur has a total of 180 co-authors. Here are the top co-authors by number of shared publications:
- Gianna Mastroianni Kirsztajn
Universidade Federal de São Paulo
13 shared publications - Helio Tedesco-Silva
Universidade Federal de Sao Paulo, Brasil
6 shared publications - José Osmar Medina-Pestana
Universidade Federal de São Paulo
6 shared publications - Leonardo V. Riella
Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA
5 shared publications - Andrea Carla Bauer
Hospital de Clínicas de Porto Alegre
4 shared publications - Gaetano La Manna
Department of Medical and Surgical Science (DIMEC), Alma Mater Studiorum - University of Bologna, Bologna, Italy
4 shared publications
Latest Publications
- 1 March 2027
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 49 (1)
Nefropatia por IgA: estratégias de tratamento em evolução
RESUMO A nefropatia por IgA é considerada a mais frequente entre as doenças glomerulares, tem apresentações clínico-laboratoriais e histopatológicas bastante diversas e potencial de progressão para estágios avançados de DRC conforme diversas características subjacentes. O maior conhecimento da sua patogênese, que envolve pelo menos uma sequência de 4 fatores desencadeantes principais, possibilitou o desenvolvimento de alternativas terapêuticas, que podem atuar em diferentes etapas de sua gênese, inclusive fármacos direcionados a alvos específicos ao longo desse processo. Já está bem definido que as medidas ditas renoprotetoras são essenciais para o tratamento de suporte, envolvendo modificação no estilo de vida (dieta saudável, exercícios físicos, controle de peso, cessação do tabagismo, restrição de sódio, controle da pressão arterial e medidas para redução do risco cardiovascular) e uso de fármacos, entre os quais devem ser mencionados: inibidores do SRAA e do SGLT2, antagonistas do receptor de mineralocorticoide e do receptor de endotelina A. Os recursos imunossupressores concentraram-se no passado, sobretudo, no uso de corticosteroide sistêmico, aliado à ciclofosfamida ou à azatioprina em situações especiais. Mais recentemente, surgiu a budesonida de liberação entérica, seguindo-se o desenvolvimento de fármacos direcionados a vias moleculares específicas, entre os quais se destacam os inibidores do complemento e aqueles direcionados à sinalização BAFF e/ou APRIL, entre outros. Essa diversidade de medicamentos gera oportunidades, mas também dúvidas e desafios por ocasião da tomada de decisão, exigindo definição de parâmetros que guiem a seleção das opções terapêuticas e suas combinações em prol do melhor resultado para o paciente, diante dos diferentes endótipos dessa glomerulopatia.
- 1 March 2027
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 49 (1)
Nefropatia por IgA: estratégias de tratamento em evolução
RESUMO A nefropatia por IgA é considerada a mais frequente entre as doenças glomerulares, tem apresentações clínico-laboratoriais e histopatológicas bastante diversas e potencial de progressão para estágios avançados de DRC conforme diversas características subjacentes. O maior conhecimento da sua patogênese, que envolve pelo menos uma sequência de 4 fatores desencadeantes principais, possibilitou o desenvolvimento de alternativas terapêuticas, que podem atuar em diferentes etapas de sua gênese, inclusive fármacos direcionados a alvos específicos ao longo desse processo. Já está bem definido que as medidas ditas renoprotetoras são essenciais para o tratamento de suporte, envolvendo modificação no estilo de vida (dieta saudável, exercícios físicos, controle de peso, cessação do tabagismo, restrição de sódio, controle da pressão arterial e medidas para redução do risco cardiovascular) e uso de fármacos, entre os quais devem ser mencionados: inibidores do SRAA e do SGLT2, antagonistas do receptor de mineralocorticoide e do receptor de endotelina A. Os recursos imunossupressores concentraram-se no passado, sobretudo, no uso de corticosteroide sistêmico, aliado à ciclofosfamida ou à azatioprina em situações especiais. Mais recentemente, surgiu a budesonida de liberação entérica, seguindo-se o desenvolvimento de fármacos direcionados a vias moleculares específicas, entre os quais se destacam os inibidores do complemento e aqueles direcionados à sinalização BAFF e/ou APRIL, entre outros. Essa diversidade de medicamentos gera oportunidades, mas também dúvidas e desafios por ocasião da tomada de decisão, exigindo definição de parâmetros que guiem a seleção das opções terapêuticas e suas combinações em prol do melhor resultado para o paciente, diante dos diferentes endótipos dessa glomerulopatia.
- 1 March 2027
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 49 (1)
IgA nephropathy: evolving treatment strategies
IgA nephropathy (IgAN) is the most common primary glomerular disease and is characterized by marked clinical, laboratory, and histopathological heterogeneity, with a variable risk of progression to advanced stages of chronic kidney disease depending on several underlying factors. A better understanding of its pathogenesis, which involves at least a four-hit pathogenic sequence, has enabled the development of novel therapeutic strategies targeting different stages of disease development, including agents directed at specific molecular pathways. Supportive kidney-protective therapy is now well established as the cornerstone of IgAN management and involves lifestyle modifications such as a healthy diet, regular physical activity, weight control, smoking cessation, sodium restriction, optimal blood pressure control, and interventions to reduce cardiovascular risk. Pharmacological measures include renin-angiotensin-aldosterone system and sodium-glucose cotransporter 2 (SGLT2) inhibitors, as well as mineralocorticoid receptor and endothelin A receptor antagonists. Historically, immunosuppressive treatment relied primarily on systemic corticosteroids, with cyclophosphamide or azathioprine reserved for selected clinical situations. More recently, targeted-release budesonide has emerged as a therapeutic option, followed by the development of agents directed at specific molecular pathways, particularly complement inhibitors and therapies targeting BAFF and/or APRIL signaling, among others. Although this expanding therapeutic armamentarium provides new opportunities to improve patient outcomes, it also introduces uncertainty and complexity into clinical decision-making. Therefore, defining evidence-based parameters to guide the selection and combination of available therapies according to the distinct endotypes of IgAN has become increasingly important.
- 1 March 2027
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 49 (1)
IgA nephropathy: evolving treatment strategies
IgA nephropathy (IgAN) is the most common primary glomerular disease and is characterized by marked clinical, laboratory, and histopathological heterogeneity, with a variable risk of progression to advanced stages of chronic kidney disease depending on several underlying factors. A better understanding of its pathogenesis, which involves at least a four-hit pathogenic sequence, has enabled the development of novel therapeutic strategies targeting different stages of disease development, including agents directed at specific molecular pathways. Supportive kidney-protective therapy is now well established as the cornerstone of IgAN management and involves lifestyle modifications such as a healthy diet, regular physical activity, weight control, smoking cessation, sodium restriction, optimal blood pressure control, and interventions to reduce cardiovascular risk. Pharmacological measures include renin-angiotensin-aldosterone system and sodium-glucose cotransporter 2 (SGLT2) inhibitors, as well as mineralocorticoid receptor and endothelin A receptor antagonists. Historically, immunosuppressive treatment relied primarily on systemic corticosteroids, with cyclophosphamide or azathioprine reserved for selected clinical situations. More recently, targeted-release budesonide has emerged as a therapeutic option, followed by the development of agents directed at specific molecular pathways, particularly complement inhibitors and therapies targeting BAFF and/or APRIL signaling, among others. Although this expanding therapeutic armamentarium provides new opportunities to improve patient outcomes, it also introduces uncertainty and complexity into clinical decision-making. Therefore, defining evidence-based parameters to guide the selection and combination of available therapies according to the distinct endotypes of IgAN has become increasingly important.
- Open Access
- 15 November 2026
- Published by Elsevier in American Journal of Transplantation
Anti-Nephrin Antibodies in Focal Segmental Glomerulosclerosis Recurrence After Transplantation: A Multicenter Study from the TANGO Consortium
- 15 November 2026
- Published by Elsevier in American Journal of Transplantation
Open AccessAnti-Nephrin Antibodies in Focal Segmental Glomerulosclerosis Recurrence After Transplantation: A Multicenter Study from the TANGO Consortium
- Open Access
- 2 November 2026
- Published by Springer Nature in BMC Nephrology
High plasmapheresis dependency after treatment of recurrent post-transplant focal and segmental glomerulosclerosis
- 2 November 2026
- Published by Springer Nature in BMC Nephrology
Open AccessHigh plasmapheresis dependency after treatment of recurrent post-transplant focal and segmental glomerulosclerosis
- Open Access
- 1 June 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (2)
Anticorpos anti-PLA2R: implicações na programação terapêutica e previsão de remissão na nefropatia membranosa
- 1 June 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (2)
Open AccessAnticorpos anti-PLA2R: implicações na programação terapêutica e previsão de remissão na nefropatia membranosa
- Open Access
- 1 June 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (2) , e2026E009
Anti-PLA2R antibodies: implications for therapeutic planning and the prediction of remission in membranous nephropathy
- 1 June 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (2) , e2026E009
Open AccessAnti-PLA2R antibodies: implications for therapeutic planning and the prediction of remission in membranous nephropathy
- Open Access
- 28 May 2024
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 10 (6) , e1651
Multiple-target Therapy for Posttransplant Focal Segmental Glomerulosclerosis
Background. There is no consensus on the ideal strategy to treat posttransplant focal segmental glomerulosclerosis. The multiple-target therapy, which consisted of high-dose intravenous cyclosporine, prednisone, and plasmapheresis, showed favorable results. Methods. This single-center, prospective study sought to evaluate the multiple-target therapy in an independent cohort of patients. Results. Thirteen patients with posttransplant focal segmental glomerulosclerosis received multiple-target therapy. Complete remission was achieved in 2 patients (15.4%), and partial remission in another 2 patients (15.4%). Four patients (30.7%) did not show remission, and 5 patients (38%) lost the graft because of posttransplant focal segmental glomerulosclerosis during the 12-mo follow-up. Premature discontinuation of treatment occurred in 10 patients (77%), all associated with infectious adverse events. Cytomegalovirus was the most common complication, and preemptive therapy was used instead of prophylaxis. Conclusions. In this cohort of patients, the efficacy of the multiple-target therapy was poor and limited by the high incidence of infectious adverse events. Export
- 28 May 2024
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 10 (6) , e1651
Open AccessMultiple-target Therapy for Posttransplant Focal Segmental Glomerulosclerosis
Background. There is no consensus on the ideal strategy to treat posttransplant focal segmental glomerulosclerosis. The multiple-target therapy, which consisted of high-dose intravenous cyclosporine, prednisone, and plasmapheresis, showed favorable results. Methods. This single-center, prospective study sought to evaluate the multiple-target therapy in an independent cohort of patients. Results. Thirteen patients with posttransplant focal segmental glomerulosclerosis received multiple-target therapy. Complete remission was achieved in 2 patients (15.4%), and partial remission in another 2 patients (15.4%). Four patients (30.7%) did not show remission, and 5 patients (38%) lost the graft because of posttransplant focal segmental glomerulosclerosis during the 12-mo follow-up. Premature discontinuation of treatment occurred in 10 patients (77%), all associated with infectious adverse events. Cytomegalovirus was the most common complication, and preemptive therapy was used instead of prophylaxis. Conclusions. In this cohort of patients, the efficacy of the multiple-target therapy was poor and limited by the high incidence of infectious adverse events. Export
- Open Access
- 8 February 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (6) , 1016-1026
Recurrence of membranous nephropathy after kidney transplantation: A multicenter retrospective cohort study
- 8 February 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (6) , 1016-1026
Open AccessRecurrence of membranous nephropathy after kidney transplantation: A multicenter retrospective cohort study
- Open Access
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 69 (suppl 1) , e2023S117
Kidney diseases in women: difference in risks and opportunities
Gender differences in access to healthcare and education persist and negatively affect women in different regions of the world. This is also true in the context of chronic kidney disease (CKD), a condition that affects approximately 10% of the adult population worldwide1 1 Piccoli GB, Rukhaimi M, Liu ZH, Zakharova E, Levin A. What we know and do not know about women and kidney diseases; questions unanswered and answers unquestioned: reflection on world kidney day and international woman's day. Braz J Med Biol Res. 2018;51(7):e7315. https://doi.org/10.1590/1414-431x20177315 https://doi.org/10.1590/1414-431x2017731... .
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 69 (suppl 1) , e2023S117
Open AccessKidney diseases in women: difference in risks and opportunities
Gender differences in access to healthcare and education persist and negatively affect women in different regions of the world. This is also true in the context of chronic kidney disease (CKD), a condition that affects approximately 10% of the adult population worldwide1 1 Piccoli GB, Rukhaimi M, Liu ZH, Zakharova E, Levin A. What we know and do not know about women and kidney diseases; questions unanswered and answers unquestioned: reflection on world kidney day and international woman's day. Braz J Med Biol Res. 2018;51(7):e7315. https://doi.org/10.1590/1414-431x20177315 https://doi.org/10.1590/1414-431x2017731... .
- 1 August 2021
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 16 (8) , 1247-1255
Recurrence of IgA Nephropathy after Kidney Transplantation in Adults
Background and objectives: In patients with kidney failure due to IgA nephropathy, IgA deposits can recur in a subsequent kidney transplant. The incidence, effect, and risk factors of IgA nephropathy recurrence is unclear, because most studies have been single center and sample sizes are relatively small. Design, setting, participants, & measurements: We performed a multicenter, international, retrospective study to determine the incidence, risk factors, and treatment response of recurrent IgA nephropathy after kidney transplantation. Data were collected from all consecutive patients with biopsy-proven IgA nephropathy transplanted between 2005 and 2015, across 16 “The Post-Transplant Glomerular Disease” study centers in Europe, North America, and South America. Results: Out of 504 transplant recipients with IgA nephropathy, recurrent IgA deposits were identified by kidney biopsy in 82 patients; cumulative incidence of recurrence was 23% at 15 years (95% confidence interval, 14 to 34). Multivariable Cox regression revealed a higher risk for recurrence of IgA deposits in patients with a pre-emptive kidney transplant (hazard ratio, 3.45; 95% confidence interval, 1.31 to 9.17) and in patients with preformed donor-specific antibodies (hazard ratio, 2.59; 95% confidence interval, 1.09 to 6.19). After kidney transplantation, development of de novo donor-specific antibodies was associated with subsequent higher risk of recurrence of IgA nephropathy (hazard ratio, 6.65; 95% confidence interval, 3.33 to 13.27). Immunosuppressive regimen was not associated with recurrent IgA nephropathy in multivariable analysis, including steroid use. Graft loss was higher in patients with recurrence of IgA nephropathy compared with patients without (hazard ratio, 3.69; 95% confidence interval, 2.04 to 6.66), resulting in 32% (95% confidence interval, 50 to 82) graft loss at 8 years after diagnosis of recurrence. Conclusions: In our international cohort, cumulative risk of IgA nephropathy recurrence increased after transplant and was associated with a 3.7-fold greater risk of graft loss.
- 1 August 2021
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 16 (8) , 1247-1255
Recurrence of IgA Nephropathy after Kidney Transplantation in Adults
Background and objectives: In patients with kidney failure due to IgA nephropathy, IgA deposits can recur in a subsequent kidney transplant. The incidence, effect, and risk factors of IgA nephropathy recurrence is unclear, because most studies have been single center and sample sizes are relatively small. Design, setting, participants, & measurements: We performed a multicenter, international, retrospective study to determine the incidence, risk factors, and treatment response of recurrent IgA nephropathy after kidney transplantation. Data were collected from all consecutive patients with biopsy-proven IgA nephropathy transplanted between 2005 and 2015, across 16 “The Post-Transplant Glomerular Disease” study centers in Europe, North America, and South America. Results: Out of 504 transplant recipients with IgA nephropathy, recurrent IgA deposits were identified by kidney biopsy in 82 patients; cumulative incidence of recurrence was 23% at 15 years (95% confidence interval, 14 to 34). Multivariable Cox regression revealed a higher risk for recurrence of IgA deposits in patients with a pre-emptive kidney transplant (hazard ratio, 3.45; 95% confidence interval, 1.31 to 9.17) and in patients with preformed donor-specific antibodies (hazard ratio, 2.59; 95% confidence interval, 1.09 to 6.19). After kidney transplantation, development of de novo donor-specific antibodies was associated with subsequent higher risk of recurrence of IgA nephropathy (hazard ratio, 6.65; 95% confidence interval, 3.33 to 13.27). Immunosuppressive regimen was not associated with recurrent IgA nephropathy in multivariable analysis, including steroid use. Graft loss was higher in patients with recurrence of IgA nephropathy compared with patients without (hazard ratio, 3.69; 95% confidence interval, 2.04 to 6.66), resulting in 32% (95% confidence interval, 50 to 82) graft loss at 8 years after diagnosis of recurrence. Conclusions: In our international cohort, cumulative risk of IgA nephropathy recurrence increased after transplant and was associated with a 3.7-fold greater risk of graft loss.